Andrew Astor - Mar 5, 2022 Form 4 Insider Report for NEPHROS INC (NEPH)

Role
President, CEO & CFO, Director
Signature
/s/ Christopher Melsha as attorney-in-fact for Andrew Astor pursuant to Power of Attorney previously filed.
Stock symbol
NEPH
Transactions as of
Mar 5, 2022
Transactions value $
$40,001
Form type
4
Date filed
3/7/2022, 04:44 PM
Previous filing
Dec 16, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NEPH Common Stock Options Exercise $40K +14.8K +19% $2.70 92.8K Mar 5, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NEPH Warrants (right to buy) Options Exercise $0 -14.8K -100% $0.00* 0 Mar 5, 2022 Common Stock 14.8K $2.70 Direct
holding NEPH Stock Option (right to buy) 64.4K Mar 5, 2022 Common Stock 64.4K $4.14 Direct F1
holding NEPH Stock Option (right to buy) 46.5K Mar 5, 2022 Common Stock 46.5K $2.64 Direct F2
holding NEPH Stock Option (right to buy) 5.56K Mar 5, 2022 Common Stock 5.56K $4.50 Direct F3
holding NEPH Stock Option (right to buy) 22.2K Mar 5, 2022 Common Stock 22.2K $5.85 Direct F4
holding NEPH Stock Option (right to buy) 20K Mar 5, 2022 Common Stock 20K $8.30 Direct F5
holding NEPH Stock Option (right to buy) 152K Mar 5, 2022 Common Stock 152K $7.07 Direct F6
holding NEPH Stock Option (right to buy) 38.6K Mar 5, 2022 Common Stock 38.6K $6.82 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On 2/13/17, the Reporting Person was granted an option to purchase 64,399 shares of common stock of the Company. Options to purchase 8,049 shares vested on 2/13/18; options to purchase 24,150 shares vest quarterly in 12 equal amounts commencing on 5/13/18; and options to purchase 32,200 shares vested upon achievement of previously disclosed performance measures.
F2 On 5/1/17, the Reporting Person was granted an option to purchase 46,525 shares of common stock of the Company. Options to purchase 5,815 shares vested on 5/1/18; options to purchase 17,447 shares vest quarterly in 12 equal amounts commencing on 7/1/18; and options to purchase 23,263 shares vested upon achievement of previously disclosed performance measures.
F3 100% vested.
F4 On 12/19/18, the Reporting Person was granted an option to purchase 22,223 shares of common stock of the Company. Options to purchase 5,555 shares vested on 12/19/19 and options to purchase 16,668 shares vest quarterly in 12 equal amounts commencing on 3/19/20.
F5 On 12/16/19, the Reporting Person was granted an option to purchase 20,000 shares of common stock of the Company. Options to purchase 5,000 shares vest on 12/16/20 and options to purchase 15,000 shares vest quarterly in 12 equal amounts commencing on 3/16/21.
F6 On 8/24/20, the Reporting Person was granted an option to purchase 152,064 shares of common stock of the Company. Options to purchase 38,016 shares vest on 8/24/21 and options to purchase 114,048 shares vest quarterly in 12 equal amounts commencing on 11/24/21.
F7 On 12/14/21, the Reporting Person was granted an option to purchase 38,612 shares of common stock of the Company. Options to purchase 9,653 shares vest on 12/14/22 and options to purchase 28,959 shares vest quarterly in 12 equal amounts commencing on 3/14/23.